Pro­to­cols: Bavar­i­an col­lab­o­rates with BMS on lung can­cer study; Eleven com­pletes Roche deal; In­tel­lia chief an­tic­i­pates new CRISPR tweaks

Fol­low­ing up on its big set­back for non-small cell lung can­cer, Bris­tol-My­ers has agreed to sup­ply its check­point drug to Den­mark’s Bavar­i­an Nordic, which plans to en­roll 165 pa­tients in a Phase II lung can­cer study that will get a com­bi­na­tion of Op­di­vo and its anti­gen-tar­get­ing CV301. The study will fo­cus on pre­vi­ous­ly treat­ed pa­tients. Op­di­vo is al­ready ap­proved in the sec­ond-line set­ting. There has been an ex­plo­sion of col­lab­o­ra­tions in im­mune-on­col­o­gy over the past two years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.